<SEC-DOCUMENT>0001129928-13-000006.txt : 20130208
<SEC-HEADER>0001129928-13-000006.hdr.sgml : 20130208
<ACCEPTANCE-DATETIME>20130208135804
ACCESSION NUMBER:		0001129928-13-000006
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130208
FILED AS OF DATE:		20130208
DATE AS OF CHANGE:		20130208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		13586100

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6K FORM
<TEXT>
<html>
<head>
    <title>form6-k.htm</title>
    <!--Licensed to: Oncolytics Biotech Inc-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<br>
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Form 6-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Report of Foreign Private Issuer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Rule&#160;13a-16 or 15d-16</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the month of February 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission File Number 000-31062</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Translation of registrant&#8217;s name into English)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Suite&#160;210, 1167 Kensington Crescent NW</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Calgary, Alberta, Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Address of principal executive offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form&#160;20-F&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#254;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form&#160;40-F&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">No&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#254;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NUMBER</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="69%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">News Release Dated February 8, 2013:<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>Oncolytics Biotech&#174; Inc. Announces Additional Positive REOLYSIN&#174; Clinical Trial Data from Phase 2 Study in Squamous Cell Carcinoma of the Lung</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="4" valign="top" width="39%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Registrant)</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date:&#160;&#160;January 28, 2013</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">/s/&#160;&#160;Kirk Look</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Kirk Look</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1 CHARTER
<SEQUENCE>2
<FILENAME>ex99.htm
<DESCRIPTION>RELEASE
<TEXT>
<html>
<head>
    <title>ex99.htm</title>
    <!--Licensed to: Oncolytics Biotech Inc-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<br>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><img src="onclogo.jpg" alt=""><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">210, 1167 Kensington Cr. N.W.</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Calgary, Alberta</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>

<br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR IMMEDIATE RELEASE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> Inc. Announces Additional Positive REOLSYIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> Clinical Trial Data from Phase 2 Study in Squamous Cell Carcinoma of the Lung</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CALGARY, AB, --- February 8, 2013</font> - Oncolytics Biotech Inc. (&#8220;Oncolytics&#8221;) (TSX:ONC, NASDAQ:ONCY) today announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> in combination with carboplatin and paclitaxel (REO 021).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The analysis examined percent best overall tumour changes between pre-treatment and up to six treatment cycles. Of 20 evaluable patients, 19 (95%) exhibited overall tumour shrinkage, (mean (20 patients): 33.7% shrinkage).&#160;&#160;A waterfall graph showing individual patient data will be available on the Company&#8217;s website at <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.oncolyticsbiotech.com/presentations</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;It&#8217;s exciting to have 95% of patients in this study exhibit tumour shrinkage and these results further suggest that REOLYSIN may have potential use in neoadjuvant (pre-surgical) settings,&#8221; said Dr. Brad Thompson, President and CEO of Oncolytics. &#8220;Based on these findings we intend to continue to look at REOLYSIN as a treatment for cancers of the lung and cancers that metastasize to the lung.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The study enrolled patients with metastatic or recurrent squamous cell carcinoma of the lung.&#160;&#160;The primary endpoint of the study is objective tumour response rates, and the secondary objectives include progression free survival and overall survival. To date, the Company has observed nine partial responses (PR), nine stable disease (SD) and three progressive disease (PD) by RECIST criteria for a disease control rate (complete response (CR) + PR + SD)) of 86%. The study continues to enroll patients.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About SCC Lung Cancer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The American Cancer Society estimates that in 2013, approximately 228,190 new cases of lung cancer will be diagnosed. Approximately 84% of all lung cancers are classified as non-small cell lung cancer (NSCLC); squamous cell carcinomas account for approximately 25% of all lung cancers. Lung cancer is by far the leading cause of cancer death among both men and women. There will be an estimated 159,480 deaths from lung cancer in the United States in 2012, accounting for around 27% of all cancer deaths. More people die of lung cancer than from colon, breast, and prostate cancers combined. For more information about SCC lung cancer, please go to <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.cancer.org</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.&#160;&#160;Oncolytics&#8217; clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font>, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">This press release contains forward-looking statements within the meaning of the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act of 1934, as amended, and forward-looking information within the meaning of Canadian securities laws. Statements, other than statements of historical facts, included in this press release that address activities, events or developments that Oncolytics expects or anticipates will or may occur in the future, including such things as, the Company's expectations related to the Phase II squamous cell carcinoma of the lung trial of REOLYSIN in combination with carboplatin and paclitaxel, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">and other such matters are forward-looking statements and forward-looking information and involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements and forward-looking information. Such risks and uncertainties include, among others, risks related to the statistical sufficiency of patient enrollment numbers in separate patient groups, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statement and forward-looking information. Investors are cautioned against placing undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update these forward-looking statements and forward-looking information, except as required by applicable laws.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR FURTHER INFORMATION PLEASE CONTACT:</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Equicom Group</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Nick Hurst</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">300 5<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Ave. SW, 10<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Calgary, Alberta, T2P 3C4</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Tel: 403.218.2835</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Fax: 403.218.2830</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">nhurst@tmxequicom.com</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td valign="top" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dian Griesel, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Susan Forman</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">396 West Broadway, 2<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">New York, NY&#160;&#160;10012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Tel:&#160;&#160;212.825.3210</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Fax:&#160;&#160;212.825.3229</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">sforman@dgicomm.com</font></font></div>
</td>
<td valign="top" width="28%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-30-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>onclogo.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 onclogo.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X0E(17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````0````<@$R``(````4````@H=I``0````!````E@```+8```$L````
M`0```2P````!4&%I;G0N3D54('8U+C`P`#(P,#@Z,#4Z,C(@,34Z,CDZ,S@`
M``*@`@`$`````0```\"@`P`$`````0```.$`````````!@$#``,````!``8`
M``$:``4````!```!!`$;``4````!```!#`$H``,````!``(```(!``0````!
M```!%`("``0````!```(+`````````!(`````0```$@````!_]C_X``02D9)
M1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$
M``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,
M#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(
M`"8`H`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"
M!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($
M`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#
M!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&
M!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S
M-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/55C]2^
ML3,?,_9O3\=_4^I@!S\>DAK:VGZ+LS)?^BQMWYG^%_X-%^L?4KNF])MOQFA^
M786T8C#WNN<*:/\`->_U%/HG1Z.D8+<:LFVYY-F5DNU?=<[W77VN^DYSW)I)
M)H:=RIH[_KT[WBKI=0.OI.?>YP_DNM:QK/\`P-*GZRW8V37A]?PSTRVXAE&2
M'BW%L<>*VY(#/1M?^95D,8MY`S<+%S\6W#S*VW8][=ME;N"#_K[7)<)&Q/U4
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M[/HUTX=3_.R+K?\`HUVUK*HQ.HGK?7.H=),9^+E,!Q["6U9-+J:G.Q7S[:K=
M_OQLK_!6?SGZ&Q=!]7^E6=,P7-R;!=G95CLG.N:(#KK/I[/^"K;MJJ_X-B:K
MK+[,_P"QG%>T>M91ZG,>FSU6W/9M]M-WT&6?03*T%Z:D_P",EH?5&]F3D]:R
M:V65-NS`[T[FEEC3Z-#;*[*W?1?7:U]:I=-_98R,P?6P5?M0WV;'9X'H^A/Z
MN.FNR?U;[/L^DVG]-ZG])]ZZG)R319C,%;K/M-OI%S>&#T[;O4?_`"/T/I_]
M<4<_+=B8_K-J=<2]C(;PT/<&>K:[W;**MWJ76;?T=:/#IO\`+X:*<SJ0>[ZJ
MY#?JN&L=Z3AB#'`9^=^E^S_1VV?SOI?\(L[_`+!3TN"RAEVSZ&V.H"R/W?\`
ME'[=ZG_7O4718.<[+?>PU%@H>&BUIW56`M;9NHMAGJ;-WIV^S^=3?:\G]I?8
M_0'I>GZOK[C$3LV;?3V^K_(]3Z"1`-'3]W93S^8WJCO\7%S>J!YSSAN%H?K9
MW]/U-O\`A?2V>I_PBV>F=9Z3>S'Q*,RFS(-;0*FO!<2UNY_M^E[6M1^I=0=@
MMH(I-WKV^D2#`8-EEWJ6.AWM_0^G_7L5JI_J5L?I[FAVAD:C\UVB(%'0[`#5
M3S'7,;)Z+E5Y?1+1C.ZSD,Q,FES/4J;==(KZI75+?3R*MOZ?_`Y?^&_2+8P.
MA=.PL!^#Z8R*[B7Y3\B+'WV.ULNRG/\`YU[W?^HT3IW479K0\UBC<W=Z+W'U
MF:QLR*-GZ&S]_P#2V(N5E.Q[,9C:7W?:+342R/8!7;?ZC]WMV?H?3_ZXD`-3
MT*GG>G=%Z/9]9NLX]F!COHJKQ#56ZEA8TO;=ZOI,<WTV[]OZ38K7UI'ZWT"!
MQU*O@<?H[_!;&!E.S,87NJ?02^QGIV:.'IO?3+OZ_I[U80$1PT.NO_=*>;^L
MF_\`:N`>HA[OJ^&O^TA@<:_7D>A^T&U>[['_`%_U;U?Z0KW2S]6/M3OV.,3[
M0:_>[$#/H`C1[Z!M^G^8KV/E&[(RJ36Y@QGM8'NX?NKKNWL_J^KZ?]A4^H]:
MLP+KV?8[KZZ:&W"VL%P+WFYM>/M:USO=Z'\[[_2]6OUO39[TM`>+]BGGLRGH
M[,_.O;G]-R;;+7.MHZO6'VL</8ZC&O=978S$;M_0U?9K_P#@UT'U9O%_1Z7M
MP?V:P%[68^H;M#C%M(<VJST;OYROU*JE=SLHX>*_(%3[RR/T=8EWN<&;O^+K
MW>I;_P`$I8MYOK+SZ9@Q^B?ZC?\`/V5I"-2W_!3_`/_1]56;U[]@_8'?M[T/
ML<_]J(C=_P`%^?ZO_%?I%\SI(2V.WUV4^Z,H^J3JM^-D]79A]JZAU'T8_D_H
MG>S^VMKZL_\`-3T[/^;_`*.^?T\3Z_\`Z$?:/UO_`+=7SBDHX[CY?I_W*?M?
MJI)?*J2E0_522^54DE/U4DOE5))3]5)+Y5224_522^54DE/U4DOE5))3]5)+
MY5224_522^54DE/_V?_B#%A)0T-?4%)/1DE,10`!`0``#$A,:6YO`A```&UN
M=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94`````$E%0R!S4D="````
M``````````````#VU@`!`````-,M2%`@(```````````````````````````
M````````````````````````````````````$6-P<G0```%0````,V1E<V,`
M``&$````;'=T<'0```'P````%&)K<'0```($````%')865H```(8````%&=8
M65H```(L````%&)865H```)`````%&1M;F0```)4````<&1M9&0```+$````
MB'9U960```-,````AG9I97<```/4````)&QU;6D```/X````%&UE87,```0,
M````)'1E8V@```0P````#')44D,```0\```(#&=44D,```0\```(#&)44D,`
M``0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="($E%0S8Q.38V+3(N,0``
M````````````$G-21T(@245#-C$Y-C8M,BXQ````````````````````````
M``````````````````````````````````````````!865H@````````\U$`
M`0````$6S%A96B``````````````````````6%E:(````````&^B```X]0``
M`Y!865H@````````8ID``+>%```8VEA96B`````````DH```#X0``+;/9&5S
M8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H```````````````6245#
M(&AT='`Z+R]W=W<N:65C+F-H````````````````````````````````````
M`````````````````````````&1E<V,`````````+DE%0R`V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``````````````+DE%
M0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``
M``````````````````````````!D97-C`````````"Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ```````````````L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````
M````````````````````````````=FEE=P``````$Z3^`!1?+@`0SQ0``^W,
M``03"P`#7)X````!6%E:(```````3`E6`%````!7'^=M96%S``````````$`
M```````````````````````"CP````)S:6<@`````$-25"!C=7)V````````
M!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!``$4`2@!/`%0`60!>`&,`
M:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`L@"W`+P`P0#&`,L`T`#5
M`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K`3(!.`$^`44!3`%2`5D!
M8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!T0'9`>$!Z0'R`?H"`P(,
M`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8`J("K`*V`L$"RP+5`N`"
MZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#E@.B`ZX#N@/'`],#X`/L
M`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V!,0$TP3A!/`$_@4-!1P%
M*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2`99!FH&>P:,
M!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^`@+"!\(
M,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)9`EY"8\)I`FZ"<\)Y0G[
M"A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@`N8"[`+R`OA"_D,
M$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-C@VI#<,-W@WX#A,.+@Y)
M#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$`D0)A!#$&$0?A";$+D0
MUQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3`Q,C$T,38Q.#
M$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X%9L5O17@%@,6)A9)%FP6
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MUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB
M/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G02E!:D&L0>Y",$)R0K5"
M]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C7
M21U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/
M24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"
M5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<
MUETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K
M9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]K
MIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9PX'$Z<95Q\')+<J9S`7-=
M<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[
MPGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!:X'-@C""DH+T@U>#NH0=
MA("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-
M,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.339.VE""4BI3TE5^5R98T
MEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?
M^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFI
MJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!UL.JQ8+'6LDNRPK,XLZZT
M);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$
MOO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)
MN<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1/-&^TC_2P=-$T\;42=3+
MU4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@
MO>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&
M[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY
M./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____;`$,``0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`'`!X`,!(@`"$0$#
M$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_Q`"U$``"`0,#
M`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S
M8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#
M`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!
M`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q
M%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(
MR<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/[^
M****`"BBB@`HKAOB)\2?`_PG\+:GXX^(_BK0/!?A#18&N-4\0^)=4M-(TNS0
M<*KW5[+%&\\[$0VMM$9+FZN'CM[>*2615K\"?VE_^#@+X7^%+F_\-_LS?#F\
M^)^H6YDMT\>>-YKKPMX*,X8*+G2_#\2?\)5XAL\A0HO7\)/.'#VCSHJL_@YO
MQ)D^104\SQE*AS1YH44^?$3CIK&EHW:^OJC6E1J5I<M.+EW?1?\`#G]%]%?P
M^ZK_`,%._P#@J7^TKJMSI_PSU_QE"D[L/^$6^`'PM2=K42D%(HM2L-'\1^+H
MHE#1HLD^O/<;AM\QY'I\7@#_`(+>:^HU(7'[>48G`<*_C_XE^'R%;)'_`!+I
M?$FEF'Z?9(F'\2C*Y^1_XB7AZMI8#AW/\?2_Y^TL+:'2UG[U[W?;;[NCZE)?
M%5I+M[U^WY7^[[C^W^BOX<[KXA_\%I?@2IU;6=0_;/TZRLQYL^H^+=(\9_$+
M0H8DSN:ZG\2:?XHT=H@$9I#<RDA2690L1(]P^"__``7Q_:F\!WUOI7QP\$^"
M_C!H]N_DZC/'8'X=>.$8,L4Q%YI4$_AIS#B1A:3>$X9Y70Q27<:%YE=#Q.RA
M58TLSR_-<H;WJ8O#/V4;6O?E_>2W7\.E-*_O-:-OZA4E_#J4IVW]ZUMO5/K]
MQ_8Y17YS_LF?\%0?V6/VNGL]`\(>*)?!/Q)N44'X8_$#[)HGB.[G"$S)X=NQ
M<S:+XKC0I(PCT34)]3CM@+B^TRQ7<B_HQ7WV!S'!9GAX8K`8FEBL/-7C5I2Y
MHOOV:MYI''.$Z<G"<7&2W3_SZA1117:2%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%?$W[;7[<GPG_8C^&@\9
M^/IO[9\5:VEU:?#[X<Z7=11Z_P",M7@1`^QG60:9H&FF:&;6]?GAEMK&%H[>
MWBOM6NM/TR\]M_:'^//@?]FCX0>-OC1\1;O[-X7\%Z//?RP0O&-0UC5)&2VT
M;P[I,4A59M5U[4Y[;3;%&98DFG$UR\5K'--'_%5X0\,_M#_\%?OVR[^_U6_G
ML8+^9=0\1:SLN+OPO\&_A597VVRTC2H&9`T\<4QT[1[`-#<>)?$5S<:SJCQ^
M?K>I0_"\7\45\J6%RS*:/UO/,SE[+"4(^][!/EM7K1MI;F]R+:4K2?,K'7A:
M$:SG.J[4J4>>?GV6^BON]?3<DUCQ!^W'_P`%?OCE_9UA#>:WI^FW9N;70;.X
MN=$^#?P>T.ZG>".ZU"X<S6L%SY#2(^HW0U/Q;XA>&>WL5N@L-A!_0/\`LF_\
M$0?V9?@G8Z9X@^-4(_:!^(T*Q3W(\002V?PWTR]`5GATOP<DJC6X8V#QM<^+
MIM2AOE`NAH^G2L(X_P!.OV</V;?A3^RS\,-&^%'PBT"#1?#^F11R7]\\<3ZY
MXGUHQ(E[XD\3:BD<;ZGK.HLBM-,RI!;PK#8:=;V>G6MK:0>^5RY#P#@\,WF6
M?MYSG=>;K5JN*;JT*,I+6G"C)NE5L]'.I![>ZH]:JXZ4TZ>'Y:5%6Y>6-F[V
MW[6MWO=LY_PSX5\-^#=)M]!\*>']$\,Z):(L=IH_A[2K'1M,M8U4(L=O8Z=!
M;6L**JJH6.)<`=3VZ"BBOT&G"-."A",816T8148KT2V.(*^5OCS^Q3^S%^TO
MI]S:?&#X1>$/$NH7$;I'XJMM.30O&MBSY(FL?%VB&QU^-HW/FK!-?3V4S@+=
M6MQ#NB;ZIHK+$87#XN#I8FA1KTY?%"M2IU8O;I.,NW3?J4I2C\+:]#^//]MC
M_@B1\5?@1%??%3]EK6-?^*_@?1Y#JUQX1=1%\6?",5JYNUO](?25M8?&-OIY
MACG,VD0:?XD@$:-#HFH"U:['K'_!-?\`X+,ZYX9U/0_@-^V+KD^J^'Y[BWT'
MPE\:-89AK7ABZ686MOH_Q,ED7SM3T@RN+5/%LX&JZ+(JGQ(UW8"[U?2OZM*_
MG-_X*[_\$L=)\=Z'XD_:D_9V\/1V/Q'TFVOO$'Q6\`Z+:%;?Q_I=M$9M1\6Z
M!I]N-D/C/354WNKV-M"R^++);RY2"7Q./^)Y^89QPOC>&:\L_P"$9S@H:X_)
M6G/#8G#Z<[ITKI7BFW:VB>C/0HXF.(4</BO>3TA53M.&U[.S7O>[>_9>9_11
M97EO?VT-W:RQ7%M<PQ7%M<6\JSV]Q;SKYD$\$R9CFBFB*2QRQL\;QNKH[*0Q
MM5_,7_P1%_X*&7NHS6/[&7QBUJ2]O(K29_@3XEU:Z9[B6TTZVDN+WX97MY,3
M).]E903:AX.>9G=+"VO]`1UBM-!LJ_ITK[OA[/L+Q%EE',L+[JG^[KT7*\\/
MB8V]I1EHK\MU:5E>^R:.*M2E1J2IRZ:Q?\T'\,K=+_/U"BBBO<,@HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***I:CJ%KI=
ME=ZA>S);V=E:W-Y=3R':D-O:0O//*YP<)'$CN[9X`X!S0W9-]M0/Y)_^"]O[
M4][XV^+?A/\`92\+W\TGASX806'BWQW:VDCE=5^(?B6R$F@Z7<1Q_P#'P/#O
MA/4+:YMPF[=?>+;B(J)].C9/W$_X)A?L<Z?^R#^S-X<T34]/AB^*WQ"MM/\`
M''Q7U%XH_M::WJ%FLVF^$_-P7^P^"]/G&D1PAV@?5?[8U&$*FH[%_E__`&,-
M%N_VY/\`@J?HOC3Q5`VHZ/K_`,7?&/QW\307>^XMXM#\+WNJ>*]#T:X1PX;3
MOMT/ACPPELP$:6,L=LNQ%(D_NAK\IX*H1S_.,[XOQ'ON>+J8#*[_`/+G#46U
M*I&+_AU'>*C)7<??5WT]#%2]E2I8:*M[O/571N7+RKY6EHWL]D%%%%?JQYX4
M444`%%%%`!364."K`$$$$,`00>H(/4'C([XIU%`'\1__``5;_9AU/]B7]KW0
M/B]\(?M'A3PA\2-77XI_#J^TB$6<'@_XA^']5M=2\3:#IJPXCMHM.UC[!XCT
MJU&VTATS6TTB&!K339XU_K7_`&1/V@-)_:@_9W^%WQOTM8+>7QGX:M9M?TVW
M<M%H_BW3))='\7:.@8M(L6G^([#4H+1I?GN-/%I>8*7",WQ-_P`%K?@E:?%O
M]AKQKXBBM%G\0_!;6-%^)^BS+&#<)96=P-`\60"4(9$M#X6US4]2G1'0/=:3
M83,<V\>/B_\`X-X/B_/JOPR^//P/O[MI%\%>*O#?Q"\/0R.28[#QOIMWHNNV
MD'41V]E?>$=.O9%!V&?7))`/,DD4?D^5TUPWQYB<HA:&6<0X=XS#T(NU.GBH
M/VD7!7?VZ5>EO&]E+O$[Y_[1@X5I_P`6BE2YMW9)*]GWT\M-.I_2%117,>*?
M&/A+P59P:CXQ\3^'O"FG7%P+2#4/$FMZ;H5E+=LC2):Q76J7-M!)<R)'(Z0(
MYD9(Y'`VHU?JTYQA%RG)1BMY-V2^9P'3T5QWA;XA>!O'(O?^$,\9^$O%G]FF
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M7-M"2<'@/G(X[X\0_P"&QOV3OM?V/_AI+X&"YW;/*_X6KX)W^9_SS`_M?&[/
M;(KFJXS"49<M;$X>E+;EJUJ=-Z6O;GE%NUU>R\G9L:C-[1;^3[K]+_\`#7/I
MBBN4\*>-_!OC:T;4/!OBKPWXJL01F\\-Z]I>NVP],SZ7<W4(X(Q\^><'MGJZ
MVA4A4BITY1G![2BU)/OJNP@HHS7(^+/'?@OP-9+J/C3Q7X:\)Z><G[;XEU[2
M]!M>.N)]3N;6)N,X`;)Q^1.I"G%SJ2C"$=Y2=DO4#KJ*^95_;)_9,>X^RK^T
MI\##<%B@C'Q4\%`^8,?(/^)O@MSST`KW#PMXV\'>-K#^U/!WBCPYXJTXGB^\
M-ZYIFN6A]/\`2=,NKJ'/."-^0<\>N%+'8.O+DHXK#U9/[-*M3J/INH2E9]D]
M[.P^6:7O1:^3[+]7_3.JHHS_`(T5U""BN)\3_$?P!X(EM+?QGXW\'>$)[^.6
M:PA\3^)]%T"6]B@9$GDM(]6O+1[E(7D1)FA5UB:1%<JS`5T>CZQIFOZ=::QH
MNH:?J^DZA!'=:?JFE7MOJ&G7]M+DQW%G>VCRVUS`ZX*30RR(W.#QDY0K0FW!
M3@ZD4G.$9*3C?:ZT?X>0&G1116H!17DVK?'CX*^'M4OM#\1?%SX8Z!K6F3_9
MM0T?6?'OA73-4L;C8DGD7NGWVJ6]W:S>7)')Y<T2/LD1P-K`GTRPU"SU.TM[
M^PNK:]L;R"&ZM+RTN(KFUNK:X198+BWN(6:*:":)TDAFB9HY8W5T=E8&LJ=>
MC5<HTZL)RC;F49)N-^Z6J`NT45R/BKQ]X(\#QV4OC/QAX6\)Q:B\T=C+XG\0
MZ1H$5Y)`BR3):R:K=VJW+Q1NKR)"9'16#,H4YIU:L*,'4J24(1WD]$OF!UU%
M<QX5\8^$_&MC-J?@[Q-X>\5:;!<&TFU#PWK>G:[917:QI,]I-=:9<7$$5U'%
M-#*]N[B58YHW*[74G+\2_$[X<^"[J"P\8^/?!?A&]N[?[79VGB7Q5H6@W5U:
M^;)`;JWM]5OK.6:W$T4D1FB5T$B.A8,I%3*O2A%5)5*<:37\24TETM;H_O0:
MO1*[.[HKR+_A?_P+_P"BS_";_P`./X/_`/EQ1_PO_P"!?_19_A-_X<?P?_\`
M+BL_KV#_`.@FC_X,C_F.S[/[CUVBO(O^%_\`P*_Z+/\`"?\`#XC>#OZZR*]2
MLKVWU"V@O;.>"ZL[J&&YM;JVF2XM[FWGC66&XMYXR8IH9HG22*6-FCD1@R,R
MD$ZTJ]&M?V-6%3EMS<DE*U]KV[A9K=-?(MT5C:_XAT/PKI-YKWB36-*T#1-.
MB$VH:QK>H6FE:781-)'"LMYJ%]+!:6L332QQ"2>:-#))'&"7=0</P?\`$?X?
M_$!;]O`WCGPAXS72C;KJ;>%/$FC>(1IYNUE:U%\='O;P6IN5@F:W\\Q^>L,A
MC#!&P2K4XU(4I5*:J33<8.24Y6M=QCO)*^OJA:[VT.UHHHK4`HK$U[Q)X?\`
M"]A)JGB37-&\/Z;"K--J&N:I9:38Q!<$F2[OY[>!`!DDM(``.OKX'/\`MB?L
MGVUVUE<?M)?`Z&Y1_+:%_BGX+#I(.J./[7PK#TR<^V.>>MB\-0:5;$4*+E>R
MJUJ=-NS2=E.2;M=7MMI?<:C-_#%M>C[K_@_U<^EZ*X?P?\2_A[\0(&N?`_CK
MP?XQ@54=IO"WB71M?1%=2Z[VTJ\N@GRC/S$''7!S7<5I2JTZT%.E.%2+^U3D
MIQ?HT(**,UX5XU_::_9X^&EX^G_$#XW_``H\'7\>_P`[3_$/C[POI=_&4P6#
MV-SJ,5VK`'A&A#MV7M45\31PRYJU6E2CUE5JTZ45MNYRCWZ?Y#LWLG]Q[K17
MRKI?[<7['VM3K;:9^TW\#;J=F"+&OQ+\*1LSE@JHOG:K'N8L0!MSCOC(KZ*\
M.^*_#/BZQ34_"WB'0_$>G2*K)?Z#J^GZQ9.&S@I=:=<7$#`X."'P>Q-10QV$
MQ+DL/BL/6<;<RI5Z55KFO:ZA)M7L[7WMH.4)Q^*+7JOZ[G04445U$A7SG^UU
MK5UX<_94_:6\0V3%+S0?V?OC)K-JZL4=;C3?ASXBO("C`AE(EA4[E(96VD$5
M]&5\\_M9Z#=^*?V6_P!I#PQ8QO)>^(_@)\8-"M(XU+2/<ZK\._$-C;HBCDN9
M9P%4<LQ`QS7#F7M/J.+]E_%^JXGDWW]A.UO.]C2E_%I_]?(?^E(_F`_X-YM`
MM;[]J/XP^(95!NM$^!EUI]HQ`+1#7O''A%KB6/(.U]FD)%O&"$E=<D.5/]@M
M?QY?\&]7B6UT_P#:I^+7AN9U2X\0_`R_O;(,5'G2^'_&WA`RVZ$D9D,&J23[
M0?\`5V\KGY48C^PVOB?"]TWPI0]G_P!!>-YEV?UB=K^?Z6.G,/\`>);[+>^U
MEW_'T"BBBOT0X@HHHH`****`"BBB@#P3]J+PY;^+_P!FSX_>%KJ/S8/$'P5^
M*6D.FS>W_$P\$:S;J\:X/[Z.219(&&62549<$!E_EC_X-[M<FM/VMOBEX>#9
MM==^`6MW<L9=E#7&B>//`1MI0HX9HX]2NE#-RJRN!P[5_4G^U=XGMO!?[,/[
M0WBR[D$</A_X)?%+5.7V&2:T\#ZT]O;JV1B:YN1%;P#<"9Y8@#D@'^7+_@WL
M\/S7G[5WQ8\3;6%IH'P&U33I91'N5;GQ!X[\$-:Q;\91I(M'O'4!AO2&0G.S
MC\PXIUXXX']E;VOML3[7;^%RU?8_^Y/Z1WX6_P!3Q?;DC]^G_`/[$:_GP_X.
M(21^S3\$<`9/QT(YS_T(/BWZCU[?I7]!]?SW_P#!Q'_R;3\$.W_%]#^7_"`^
M+>_^<=:]_CYVX2SI_P#4*O\`T_1,,)_O-'_KXC^?OX">)OVFOV*+#X2_MH_#
M!I$\!^.=4\1>%;J8?:KKPKKDWAO5KJVUSX=?$"RC"+"VJV%I%K6B7!D5@LGV
MO2;R+5-(O%MO[5/V,OVS_A1^VM\*[7XA?#R\33]9T];:R\>>`K^YC?Q#X'\0
M/&SR6%_&JQ&[TRY\N2;1=;AA2TU:T5F"V]Y!>V-I^8__``1V^%/P_P#V@_\`
M@F?XH^$?Q3T"T\4^"M;^*_Q&T;5-,NE*2IYEIX8U*SU&PN5)ET[5M,O9X[_2
M]1LC#<V%[!;W4#B5-[?D-\<?@5^TY_P1S_:3T7XK?"S5]1UCX8ZKJ4]KX2\8
MW%M-+X=\9>&YWDNK_P"&7Q0L+5XK>'5X[6+=(JF!;U[6'Q/X8FM-3M&@T?\`
M/LCK9GP=EV5YQ257&\,9EA,-B,RPZ?-6R[$U*<85*])-/F4W&\HKE4N5)M<I
MVUU#%3J0ERPQ5.;A%REIR*R271N*TUMNC]+O^#C*WD?X7?LRW0C4I#X_\>V[
M2'!9&N?#NBRQJ%X9@_V1F95ZF-03R*^X/^")AS_P3K^#QX_Y&/XK@8Z<?$[Q
M9W_'GBOR-_X*K_M9?#7]MO\`8?\`V=?C+\/)C9ZCH/QFG\.^/_!EU<)-K'@7
MQ1J_@#6M0.E:DJK%]HT^];1)YM`UL116NJV,;R+';7L%_I]C^N7_``1,_P"4
M=?P>QW\2?%G''_53O%G^3[UZ^3XJCC?$K'XO#58UL/B>'J%>A.#O"5*I+`<D
MEYNTDXO:U]-C*M"4,#&$E:4<0HM?X?\`AS]8Z_GD_P""K7_!6?Q'\`?$NH?L
MX_LY36-O\4;&SB_X6'\0[F"'4XO`S:I9I>6?A_PS8W"R6=SXI^Q36UYJ&IZA
M!<V&C)=6UM#:W6JFY73?Z&Z_SY_VT=&U?P!_P4)^/'_"SK:YEC@_:-U[Q7J<
M=W')*VJ>#]=\8/XLT:ZAB=09K#4_"&J6;VL$6(#;R+:1[5!">MXD9QC\JRC#
M0P-5X5YCB_J=?&17OX>BZ<IR=*7_`"[JSY>6$_LV;LW:V>"I0JU7[17C&$I<
MO>UM#]O_`-F'_@CKXF_:%T31OCI^W_\`%SXI^+?&'B^RL_$%I\/(_$MVVH:7
MIFJ(M[:VWBSQ'K']IW]M?RQRAKKP]H4&FQ:.66S:_>XAEBM_T$G_`."+7_!/
M*;2_[-7X-:G;OL"?VI!\1?B`NJ9'1S/)XCD@9AD_*]LT9)Y3'%?I[H.MZ3XC
MT;2]?T&^L]3T+6M.L=6T?4]/GCN+#4=,U&W2YL;VSGB)BEM;JWDCFMY(V*21
M2(R]:U\CU%>S@>#N'\-AX0G@,/CJLHQE6QF-C]:Q.(J27O5:E:K*;?-T2LEW
M9E/$5G)N-25)/:$':,;=$NG]:'Y=_LS_`/!)/]F7]EGXMO\`%_P!J_Q/U35[
M6"2+P]HOB7Q:D^@Z!-,K13WBVVCZ?HTVMS&!W@MXO$$VIV5LKF9+4W:6]Q!^
MHM&:*]W`9;@LKHO#X##4L+0<G/V5&"A!2?Q.R[F4IRG)RF^:3W=NVVWD?A/_
M`,%>_P#@ICXD_92M]$^!OP1FL[7XS>,O#_\`PD.M>+;B&*_'P[\)7MW/I]E+
MIUC/'+9W/BG6YK/4'L3J,<EOH^GVG]H26=S/?:>4^3OV(O\`@E%-^U_X"\/_
M`+4?[;7Q3^*'C6]^)$!\2^%/""^)KL:C=>&;V1GTW6?$WB74UU#4(TUN(?;]
M+T?0!IJ66D3V,CWQEG:TM?@O_@N5X8\1Z)^WSXMUK6()UTCQEX`^'&M>$[AU
M?R)M)L/#T/AB^BMV(V?N/$.B:L9(E8LC7",P'G(6_J]_8&\8:'XY_8O_`&9=
M>\.S03::OP2^'6A.+=T9+?5O"OARR\+:_8OY8"K/8:[HVI6ERF`5GAE!`Q7Y
M;E\/]9N-\]PF=RE6P>4*4<#EKE4CA)\LZ</;UJ4)P56JE)-RFGS=$K,]&K%8
M?!T*E)VJ5N5RJ+XE?5*+UM;7IKY/?YPD_P"",'_!/"2P%A_PI*^0A#']N3XB
M_$,7_0KO$Q\4&,.,YRL`![KTQ^4G[<W_``2[\2?L/>#=3_:G_8E^*WQ0\-:?
MX$>WU+QIX5_X2.XCU_1-%DN8H/[>T37]*73Y=6TC2[B>`:QH^N6]T\.E//J,
ME]>6]I=6K_U4Y'3(S7R=^W9J>BZ3^QC^U'=^();6/2S\`_BK9R&Z*B*2ZU'P
M9JVGZ7;*&8+)<76JW5E;6L993)<S1*OS$5];G?"N13RW&3HX##X'$4,+B*V'
MQ>"A]4KX>K3I<\:D*E!TGHX)6DWOI;5/GH8FLJL%.I*I&4HQ<9N\7=I:I[VU
M:/S9_P""1?\`P4W\2_M7-J_P+^-_V*7XQ^%/#I\0Z'XOM((K"/XA^&M.N;73
M]1_M&P@2.SM/%>D2WEK<W@TV.*SU73IY-0BL[22QO]_[L5_#A_P1`TG6=2_X
M*#_#N\TM)C9:%X*^)VJ>(7C4LD>D2^$+_18?M!Z+#)KVK:+""Q`\^2%0"Q7'
M]Q]<GAQFV-S?AU5L?4]M6PV*J815FO?K4Z=.C.,ZC^U4_>.,IWO)QOH5CZ,*
M-?EIZ1<(RMVOT_#R/Y)_^#BG_DMW[.__`&2OQ)_ZEK5^]?\`P3(_Y,'_`&6O
M^R5:1_Z5W]?@I_P<4_\`);OV=_\`LEGB3_U+3^5?O5_P3(./V!_V6N0/^+5:
M1U_Z^K^O'R!_\;'XL_[!8_\`I."*KO\`V"A_U\7Y(^[J**`<].?I7ZK==U_7
M_#G`?C-_P4]_X)<>&?VN]"NOBI\*[73_``U^T=H6GL(KC$5EI'Q2T^RC'D>'
MO$\FWR;;6[>%?)\.^)7_`'D#B'3]8>;25BFTS\D?^":W_!2SQK^QYXS;]E']
MJ^+7=.^&>FZ]<^&[*]\1P7:>(O@AXA%W):SV%_!.&NI/`YNG/VVSC#R:"[S:
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M3O\`P6@_:9U7XD_$C5+_`,,_"/PS?166OZ]:12GPO\/?#(F%U:?#WX<V=T#;
MZCXHOK8I+//,&=?M`\1>(GD!LK&^^6?V+?@CXZ_;^^/WPI^`?C3XF^(8/!?@
M7PIJLR7.H7UQJMSX5^&_A^];5=1\.^#+2[>2ULKK4;_5([2R#(;6R-T;Z6&:
MUTRWL5_NT^#OP<^'7P$^'OA[X6_"OPU8^%?!7ABS6TTS2[)/G=R2]UJ&HW39
MGU+5M2N&DO-3U2\>6\O[R:6XN)7=LUXN`ECO$>K#%8Z+P/#6!JQC_9\*T:E7
M'XZG"E.<,3*FUS48.=G!QL^:Z:=TKJ*.!O"*YJ\HRC.;TLGRVM&S3M9]5KWU
M*7P/^!_PW_9V^''AWX4_"CP[:>&O!WANS2WM+2!%-U?7>!]LUG6+W`FU36M4
MD'VC4M2NF>>YG)8E8Q'%'\R_M3_\$W_V9?VQ?&>@_$#XU:1XKO?$WAOPU'X2
MTZZ\.^++_P`/V_\`8D6JZCK,4-Q:P)-!--'?ZMJ$J7`1)2EQY4A=(H1'][45
M^HU\KP&*PD<#B,)0JX2'L^3#SIITH^ROR6A_=N^OXZG!&4H24X-QDMFMUW/Y
MW?VP/^".7[%WP:_9>^.WQ4\#:+\0K/QAX`^&GB7Q7X=N+_QY>ZE91:KHUB]W
M:-<V5Q:>5<PL\8CFB8J6A=T5T+;J_)K_`()"_L8?!7]L[XG?%OPS\;+3Q'>Z
M/X+\"Z1KNC0^'==FT&4:EJ.OII\DMS<6\,LLT:6RLJ0AHUS(S$DA=O\`5M_P
M43_Y,5_:L[_\60\=]O\`J"S_`%_SZ5_/U_P;JG_B]G[1`X_Y)=X8_P#4M^HR
M/ZG-?DN>9'E%'CGAC`TLOPM+"8JE7]OAZ=/EI5=,4Y.4%9.[\E;\#T\/6K/!
M8ANI)RC.$8.6MM$VTM%=W]-#]1%_X(5?L!*?^1<^)V,C<I^).J`,`0=K8M@P
M!QSM*MZ$5^N_ASP]I?A30M&\-:%;)8Z)X?TK3]$T>QBW&.RTO2[2&QL+2-G9
MW:.VM8(H8R[%MB#<Q/-;=%?JN!R7*LLE4GE^!P^$E5BHU'0IJ#G%;*5K7MJU
MV;9YTZM2I;VDY3MM=WM>W^2/S-_X+#?\HX/VD.W^@_#/\?\`B\GP[X_^M_\`
MKK\F/^#<4DZ]^UKP,C2_@K_Z5?$T>G'Y5^L__!8;_E'!^TAG_GQ^&?;I_P`7
ME^'7^>W]#^2W_!N)G^WOVMO^P7\%>>W_`!]_$WMW_/WK\]SAO_B*'#VNG]ES
M>KLM\9M_7?J=M#_<<1_U]A_[8?U-U^)/_!5G_@J'/^Q\FF_!WX/VVE:O\=O$
MNBC7;O5=40:AH_PV\.WIFAT_4[K3@0FI>)-5FM;F31]+NB+.TM+<:KJ<-W!/
M86&H_MM7\(G_``63\,^*_#__``4'^-=]XGANQ:^*X/`OB/PI>W`D\B_\,'P/
MX?T.V:P:0`-;6&IZ+JFCLL:JB76GW"89]SO['B+G./R7(8U<NYH5L5BJ>%EB
M(Z/#TYPJ3E4C+[%1\EH3L^7WFE>QG@:,*U?EJ:Q4)2L[ZM6TT:[GZ-_LD?\`
M!,WXN?M[>&M%_:<_;H^./Q2U70/&L?\`;?@CP3!K+?V]JGAVYE,EEK=W<ZG#
M>:1X/T/58P;G1=$T#1$FFTJ6TOQ<:?#<10M^I5M_P19_X)Y6^F?V<_P;U2[D
MV;#JEW\1?B"^J<@;I%GC\20P)(S#=\ELJ*20L87BOM']E3Q/X8\8_LU?`CQ#
MX-NK*Z\-7_PC^'O]E-8&(P6\-KX5TZRDL&2%BMM<Z=<6T^GW=DP6:RNK:6TG
M1)H70?0FX>H_,5V91PGD$<!AJE7"T,SK5\/0JUL;C.;&5L14G3C4E4=2K.>C
M<K))1^%<UWHL:E>M[22C4E3C=6A!VC%>2Z/3TO\`C^2?PB_X(R?LE?!7XQZ#
M\8?!M_\`%;S_``U.-0T?PAJ7C9W\.V^KQR;[2^N+C3=.TW7]0ALW"R1:;?:Q
M<6,[JHU"*]@W0-^MM&:*^CR_+,ORNG.EE^%HX6G4J.K.%&*C%REULM%MI;0S
MG5J5+>TFY\NBOTO:_P!]C^9G_@NY^U3^T5\,O$/P\^"7P]U+Q-X`^%?C#P5/
MXC\1>,_#TEWI=UXXUR74]8TV]\%_\)%9M'-:6&A:;8V6I:II=G/:3ZDVNP?V
MAYNGK;I+S'_!,C_@GQ_P3X^/?P9\,?$'XC^,HOC1\7M;BNKSQEX%O?'ESX;;
MP1?-?W,2:-+X6T;4=*\0W3-;)!,VMZE>75CJS3?;-*$5JXW?T?\`Q:^#?PQ^
M.O@^]\!?%GP7X?\`'?A'4`3/H_B"PBO88YPI6*]L9CMNM,U&VR7M=2TZ>UO[
M5QNM[B-B37X>?%C_`(-^_@OK&NW'B'X%_&?QW\('DD>>WT+4K"#QOIVG2,Q?
MR]*U(:EX?\0V]LF1L2_U/5+@$*?M9&17YSG'#6;0X@JY['"8;B;"58N%+*\;
M7C1E@(SY;_5H5%6H5G%Q3ESTO>]VW)9M]=*M3]BJ3E.ARNW-!N7/>WQ)6M:V
M]WN]NOUWXI_X(N_\$]?$U@UI:_!_4_"DY5U34O"_C_QQ;7T3,"`ZKJNNZO8R
M%<L52ZLKB(G!>-]HQB_LQ_\`!'_X)?LL_&RW^,'@KXH?&'5K?2[>8Z-X(U;Q
M%!8:-'J<X,27VN7/AJ#1)/$]K:V[-':Z3JMNU@9=D]]'?F&!(_SCU7_@F-_P
M52^`=B^K?L]?MAZEXUM],0W%IX9A^(/C+PK=W<<.7^SP:!XLGU;P?<R2!0?L
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M"M^S#K$_[!'_``51TGPUXFN#I?A_P;\9O%/P>\275X3!;2>"_&5QJ7AG2-?N
MV8J!IZ6&K>&O&*2.^U;2*"5F#\#^Z@$$9!!!Y!'(YY'YCFOY._\`@OK^RA>>
M'?'?@W]K;PKISMHGC>VL/`/Q.FM8FQ8>+M"MW7PEXAO&B!8)K_AVV70O.+H+
M>Z\+Z9&7,NI1U^O/_!*#]M"Q_:S_`&:]&LO$&J13?&+X26>E^"OB19S3*;[5
M(;2T-MX8\<>63YKV_BG3+,M?7!15'B&SUM?+BA,`/Y1P;7CP[G>=\(XCW8O%
MU,PRF[LJM&K\5&,FESU=(.$=+KF[:^AB8^VI4L3%\SY5"JU]FUE!]];RUMZ7
M/U,HHS17ZN>>%%%%`!1110`445#//';1//-)'%#$CRRRRN(XXHHD,DDDDC85
M$1%9F9B``,D@9-#=M].NO9;OY`?CQ_P7!^.5E\*_V)?$'@FVO4@\3_'+Q%HO
M@#2K=)=ES_8EG>0>)_&%[Y:D,]D-'T==!N^B--XALX'($_/R_P#\&\_P=N-"
M^#OQL^-^I6C1/\1?&6B>"?#\LT6'ET3X?Z?>7VHWMNS$EX+W6O%LNGS,25,W
MA\QX_<[F_)[_`(*3?M(>(/\`@H3^V=H'PZ^#4<WB7P?X7UFV^$'P>L+)FEM?
M%.O:OJUO;:_XQ@8;DCM?$&K^1%;WK")8_"N@:;J-SY8>ZA7^PO\`9>^!6@_L
MT_`;X9?`_P`.LLUEX"\,6.EWFH+'Y0UC7[AI=3\4:X8^J/K?B2^U356C8EH1
M=B#(2-57\HR>HN)>.<9GD'SY7D%)X'"UDKPJ8J;5-<FRTE4KU6];.48^9WU+
M4,)&A)MU:MJKCLDG9VOKV71:>6_T'7XJ_P#!;C]GGXT?M%?`/X3^'?@I\/\`
M6OB)KF@?%U-<UC2]#-E]KL-'?P=XET_[>\5Y=6WF0+>7=M;L(2[*\\>Y0#FO
MVJHK]#SG*Z.=9=BLLQ%6=*CBZ7LYRIJ'/I.$TX\\9;.&RMOOHCDI5'2G&:5W
M'IL?D?\`\$8?@C\8/@!^RAXA\"_&GP)K7P]\3S_&3Q9X@L-%UUK$WDVAZAX:
M\%6=M?JMC=WBI#->Z9J$*"5XY";=G\L(RY_2;XN_"+X??'7X?^(OA?\`%'PY
M8^*O!7BFQ>RU;2;U.IRLEM?65PN)[#4].N$CO-,U*T>*\T^]AANK6:.:)'7T
MK-%+`Y3AL#E6&RE+V^%P^&CA>6NN=5*225IIO6]M-=.@IS<ZDZEDN>7-;HKV
M^_8_B4_:D_X(Y_M:?"#XC:_X5^!GA#Q5\;/@]KMU%K>@:OH%QIT=Y##:'4$T
MS2_&ND37UBG_``D>@I>SVUKJD%O)8:A:7,][8-9W%[?V5G_27_P2B^$WQ(^"
M'[$'PO\`AQ\5O">H^"?&VD:M\1;S4_#>K-:M?V,.L^/_`!+JNGM<?8Y[F!?M
M-A=VUU&@EWK',@D2-^*_2"BO`R3@?*\@S7$9GE]7$Q]O2J45A:D_:4*%.=2E
M4]G1<KU/9KV2483G-1NVFKM/:IB9U:4:<HQM%IW2LW9:72T"OR\_X*`_\$Q/
MA5^V]IMCXB;4W^'OQIT#2SIF@?$/3[%+RVU/3H6EFM=!\8Z2LD#:KI5O//*U
ME=VUQ;:MI9ED^S74ELTMG)^H=%?2YCEN#S;#3P6/HPQ&&J+WZ4XIVE]FI![P
MJ0UY)K579A"<Z<E.#Y9+9_UZ'\OWPC^'_P#P68_X)\6@\">#/`OA[]I?X-:7
M,_\`8V@VNL0^)K#2[1Y'(7PW%/J7AKQYX>CDV^:VCK:7VBV<\CR06DC$R-]2
MV'_!2;_@H5>J=+C_`."6OQ(.OJBH\LFM^)+#1C*6!#"6\\%1(L6"7(.H;E^Z
M7?;NK]W**^=PW"F(RZG[#+N)<ZPN$3_=X:K'+L="A'2U.C4QN"K5:=.-O=AS
MNW?16V==2UG2@Y]91O&^WQ)7OM_PY^1'P`^*W_!6'Q_\6]!U?XP?LZ_!7X5_
M`^<FU\1>'K[Q68_&<%A/+&RZUI-[INK>+KR\UG3HV9ETK4-)TK3;_?-:7#:=
M,8;R#]=Z**^@RW`U,!1E2JYCCLQE*;G[7'3HSG!RM>%/V5&ERTT_A@^;EOH]
M=<IR4K6A&%OY5:^V_I8^%_VY/V$/A1^V_P##RR\*^-FN?#WC'PR;V[^'_P`1
M='MH9=:\,7MY"(KJUG@D,<>L:!J*QP)JFC3S0"811W-I=65[##=)^,/P3^#/
M_!6?_@F?+K7@WX8?#KPQ^T]\#;_5YM8BT'2-3^VPVMS-L2;4='TN:_T7QCX8
MU+4(HXCJ-C;V.OZ$TJ";RKBX5YY/ZAJ*\G,N%<!F&-AFE&MBLLS:"Y?[0P$X
M0JU(:7IXB%2%2E7I.RO"I%I=&KN^D*\X15-J,Z:=U":NEML[W1^&*_\`!3C]
MN2.'[-<?\$L/C*VKC$9:'5O%']G?:3GGS#\.)/W(;:"XN&4Y)#\&OD_X\^"?
M^"NW_!2.SMOAMXG^"WA_]F3X(7&IVM]JVF:_K4>EIJ1L;F.YLG\4W$UYJ?C3
MQ%'ITN+VRT[3/#FF:1+J4%I=7%IYELEQ!_3]FBN?$<+8G'4987,N(\VQ6#J.
M/ML-"&!P4:\5_P`NZU3"X:G5E3E]J"G%/0<:ZA)3ITH*2V<KSMMLGHMOZZ_G
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M_#<G_!8#_I&]HW_@SUK_`.:NOUN_9C\9_&3X@?!7PCXN^/OP[T[X3_%+6H]7
MN/$'@#2[R6_@\/P1:[J=GHL<T\US>2"]OM$MM.U*[MS<S&TGO9+61EFAEBC^
M@:*]?+<IQN!K2JXC/,QS*+IN$:.+CA?9Q;M[Z=*A3J75K)1G%/K>R2RJ3C-)
M*G"FNO(M[6MO?M^+"O!?VH/#6N^-/V;?C[X,\+:;-J_B;Q;\%OBEX9\/:3`T
M:3:GKNN>!];TW2=/A>=XX4FO=0N;>UB,TL46^10TB9S7O.1ZBEKUZ]&&(HU:
M%3X*M*I2G;27+5@X.SO[K]ZZWO:QFG:2EVZ?-/\`0_E%_P""/'[$O[5?P$_:
M^_X6!\8?@EXM\`>#X/A;XUTEM>UXZ7':-J6HW6@?8[&,6NHW4[W%PL$[J!"5
M6.&1W90!G^KJBBO'X=X?PO#67_V=@ZM:K1]O4K\U?D<^:IRWUA"-_A5V[W\C
M:O7E7GSRT?+&-O3_`#"BBBO>,3Y4_;?\&>*OB-^R+^T1X"\$:)=>(_%_B[X2
M>,M#\.:'8M"MYJNK7NDS1V=A;&XD@@\ZYE811^;-&ID9%+9;-?B]_P`$0_V2
M?VDOV</BG\<?$'QN^$?B?X<Z3X@^'_AW2=$O-?\`[.5-3U&W\127L]M:+9WU
MW,\L-NF]R8UC4.NZ169$?^DRBOGL;PYA,=GF6Y].MB*>)RRG.E2IP</93C/V
ME^92C)IKVEURVVUO?3:-:<*,Z,=%.7,WK?II^'^04445]"8GP/\`\%.OAEX^
M^,?[#7QS^&WPP\,WWC#QQXEL?`PT3PYIAMUO]3.D?$[P3KM^EN;J:"$O!I>F
MWUTRO*I,<#!-TA2-_P`W?^"&W[*W[0G[-NI_M(WOQP^%WB+X<0>+[+X56OAM
MO$']GH^L3:++X]EU46D5E>WC[+'^UM/\^63RU!G"KN*N%_H:HKYS$\-87%9_
M@>(9U\1'%8##2PU*E!P]C*$O;7<E*,K/]\]DOAWUTV5:4:,Z*T4Y<S?HE96^
M7XA7P3^W3^P%\(_VX_!%CH_C5[CPSX[\,17+^`_B3HUM!/K&@27"9N=,O[24
MQ1:]X;OY`DE[HMS-`5D7[7I]Y879>=_O:C.>E>OCL#A<RPU7!XVE"OAJT7"K
M3J1334M%*+^Q4C]B:UBWH9PG*G)3@^64=G;8_EH^%_[,W_!7O_@G%>ZCI'P&
MMO#/[0WP<?4)]1/@ZUU*UU/1)S)++)+>VGA77=4\.>+/"^L78.Z]A\)WUW:7
M<[K+=-J<L9>OK+2O^"D__!0^%8])U?\`X);?$:Z\0E=CSZ9J?BJRT>290!N7
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ME@@LTCDEN+FZF?R_GK1O^"CW_!4'P@8['XG?\$V/$?B6XB15EO\`P5IGCG2H
MIF4!7<)#9>.K)C(,,HBNXHP&.`=G/]"=%>37X>QTL37Q.$XESC"2KS]HZ3>%
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MC*-&$://\4H?&[;6F]5;\=F(JA!A0`.``!@`````=@```.U.HHK[(Y0HHHH`
M\I^-OP:\#_M`_"_QG\(?B1IHU7P;XXT.[T75K8!%NK=Y3'-8:OIMPZ2?9-8T
M2_@MM5TB\"-]EU&UMK@I)Y06OXE-3T_]HW_@C[^V6EQ;J]Y;V$T[:==7,5Q9
M^$/C3\)KV^622VF(:95E,-K']K@5YK[PGXLL$GB2XAL[6\OO[P:^4OVM_P!C
M_P"$7[9'PPNOAO\`%/3',D'GWO@_QCIB11>*/`VO/%LBU?0;QHV/E.PCCU/3
M+CS;#5K4"&[A:2.VN+?XGB[A>IG-/#X[+JWU/.LME[7`XF%X.HUR_N*TT[N,
MN5<LK/EU]UW.K"UXT9RC45Z56/)4UMUT?RNRU^R=^UQ\(OVPOA=8?$SX5:S#
M*/+MK?Q3X2O9X5\4>"->DBWSZ)XAL5;?"ZE7:POXU:PU:U`N[&9T\Q(OJ.OX
M3OBO\`OVV_\`@DI\98?'WA76=:TWP^;PV?AWXM^%+2YO/A]XYTEIA-%X?\::
M1<?:=/M+JZC@@%]X3\2HQ:[C:XT&_OS;6NIK^UO[)W_!>;X(_$*RTSPS^TWH
M=Q\&O&K+#;W'C+1[74-?^&FL7)"1B[,5I'>>)?"QNIGP+6[L]8T^V!WW&N1P
MCY/-R3C[#N3RKB:$LGSG#R=*H\2O9X3$.*5ZBKM*E2OH^64K/F]UNSM=;`N-
MZF'<:M*6L8P=W%*V^E^J[]?5_P!`E%>;_#CXO_"WXNZ2NN?##XB^"?B#I+)'
M*+_P=XFT?Q##&DJAD%R-,NKA[27!&Z&Y6*9&^5T4\5Z/D>HK]#HUJ=>"J4JE
M.K![3IR4HOT:.+7L+14<LT4$;RS21PQ1HTDDDKK''&B@EG=W(5$4`EF8@``D
MG%?!?[0/_!2[]CC]F^POO^$U^,?AOQ!XCM%E6+P/\.[RW\<^*[BXBW`VDUKH
MDTVG:)*2C_-XDU+1H!L=3+Y@$;8XO'X/`4W6QF*P^%HQOS5*]:%)*UM$I-.3
MUV5VNNY4(3J2481<I/9*_P"=NF_IJ?>Y(`))``Y)/``]23P*_E]_X*[_`/!5
MC2[W2_$W[*/[-GB&#4#?I<Z)\8OB?HEX);)+$N]MJ7P_\'ZA:OY=W-=X:P\6
MZY;S&U2R>ZT*Q:[DO+XV_P`:?MC_`/!7S]H?]L&\E^#GP%\.Z[\+_AUXIO!H
M<'ASPHU[K7Q5^(<=Y(;:/3-5U'1HC<P6NJ(XBF\*>&(LW,;W-IJFJ:M:.57[
MG_X)J?\`!&&;PWJ&A?'C]L/1K>76;)[36?!/P0N_)OK/2KQ62YM=:^)#*TUK
M?W]M(!-9^$K=I;:WF*3>(I9[SS='L?R_->),QXNJO(^$HU(86?\`R,,]E>&'
MI8>Z4X4II-WE9JZ=Y)674[Z>'AATJV*=G=>SI)7E/:]KVO:ZO=;.YUG_``1/
M_P""=-]\.K"W_:[^-&B26'C7Q'I,D/P:\+ZG:;+[POX6UFU*7OCC4;>8;[37
M/%&G3&ST.`JDMAX;N;JYG\XZ\L-E_1W444*0J$0`*JA5``4*JD[5`7"@*#@`
M`<`9R>:EK]!R#(\)P]EE#+<&DZ=-<]6I:TZ]>:7M:\]7K-I:7=E;5G%5JRK3
ME.772*_EBMHWZV[V7H%?G?\`M_?MPZM^Q=IOP7DT/X>:/X_U+XQ>/9O`T"^(
M/%\G@S1]`=+>QD35-2U6+1-;"V2RW\7VR>2&-+.TCFN<RL@A?]$*_+7_`(*;
M_L8_$[]L+2_@%#\-9OAU)+\)OB3=>,]?T/XEWNL6.@^)=*:WTU1HLATG0M>:
M:"^DLOLNH0W-JL36$\^QGDVQ/'$<LRAE.)GE*G+'Q=%4(P4')WQ%%5;*I&:U
MI<\-M%-O=(='V?M8^V7[O[7?I;_,P/C5^W]\9_V=_!-]X]^(GPY_94\0:9I>
MR6Y\-_#W]KW[5XYU.%KB&$Q^&?#?B;X2:&WB+4567>NF:?<RW<XCE,2$(-WZ
M%?`?XLK\<OA)X%^*R>#?%?@!?'&@6NO1^$?&]BFG>)='CNGG2.+4+6*691'<
MI"+[3Y\QF\TNZL;UH+<W'D)^87Q._8T^,OQ&\%^(/">F_L?_`/!.?P%JNLZ5
M>:?IOC:UF\4ZGJ_A>YN56--;T2'2/@WX6OUUC36'VO2IX-<L/LNH16MT6ECA
M>WG^WOV(OV>_'G[,7P)T?X4_$;XPZ_\`&SQ'8:GJ.J/XFUQ;M8=(M-16U\GP
MGH!U*[U#5&\/:0]O-)8MJ-[/<&2]N3%'96?V6PM?+RJIG:S*<<1#$SRVI@U)
M59TZ%.-'$1M9N?)0KU?:IO2G1FJ?)[_*IKFNI&GRWA)W3UC_`.`KN]>]WT/K
MZN2\=^)_^$,\%^+?%HL_[1_X1CPQKWB(6/F^0+PZ)I5WJGV0S!)3#]H%KY0E
M$,WE[M_EMC!ZVN*^(_A^[\6^`O&OA2PDAAO?$_A'Q+X>M)[DR"VM[G6-&O=/
MMYK@Q*\@@CFN4:8QI)((@Q1&(Q7U5=572J*@_P!ZZ514V]/WEER7OUO?\;G.
M?,G[!O[6%S^V;^SWI'QPO?!<'@*XU+Q%XGT"7P];ZU)K\4)\.ZB;$7*ZC+IV
MELRW2XE\HVO[HD@.XP:^T*^!?^";7[,'CO\`9$_9AT/X+_$;5?#>L>*-.\4^
M+]?N;SPI<:E=Z-]G\0:J]S:00W&JZ;I%Y)-#`J?:-]C$BRLR)D*6/WU7#DKQ
MKRO`2S%../EA*+QD9)*7MW'WV[:+T7SML:573=27LE:G?W?2P5^9\W_!0#6O
MB?\`'SXA_LY_LH_"&W^+GB?X02O9_%?X@^,_&X^'?PP\&ZO#J4^D7&BQ7EGX
M?\7>)/$6HV^J6FH:?-'IV@Q)]KTO4Q;O<VUE-<K^F%?DCHO[#7Q>_9L_:8^+
MG[17[)/B;P#K.A_'B[N-5^)_P5^+[Z_HFFQZ_/JU]XB;6/!_CWPOIGB"^TUQ
MK&JZO/;Z=J?AJ_M+*'5;FU#74:V`T_#.I9FI9?\`4556&^M/^TI8:%.>+CAE
M2DX+#QJJ5-^TK*%.HG%M1GS+X;,I^SU4[N6G(MD]?>N_*ZMT/6OBW^TE^V!^
MSYX(UOXI_$3]F[X6^/?A_P"$].GUOQB/@_\`&;7I_&>A>'[!//UC6[70/&OP
MT\/6&NVNDV2RWUU;6FM6UZ;:&1U@V)+)%]/_`+.'[0WP\_:C^$OACXS?"^]N
M;OPGXGBN5BBU"W^QZMI>IZ=>7&GZMHVKV8EG2VU'3KRW>*98I[BVF1HKJRN;
MNQGMKNX^3/COX3_;U_:"^%OC'X/P>#_V>/@EI/Q"\/:KX/\`$WCB#XK>/OBE
MKMEX;U^SDT[7CX;\/6_PI^']FNI7NF7%S9VSZCK?DPK/(6W2F)U]_P#V-OV7
M/"W['WP$\*?`[PMK.H^(XM"DU'5=:\2ZK"EK=Z_XDUV\DU#5]2^PQ/+#IUJ9
M72UT_3DFN&L].MK6*>ZO+D2WD_)@JN92S5J$<7+*7@VY5,=25*HL8G'D5%.G
M3K6DG+VCJ4TKJ')>[:<E#EOS)3OI&.MUI>[LK6^=W?:VOU37EOQ5U7XNZ3X?
MM)_@QX3\">,O%$FJPQ7FG?$/QKK?@;18-%^S7;W-[!J>@^#O&U[<:A'=K8PQ
M6$FEP02V\US.U\DEO%;7/J5%?1U:;JP<54G2DUI.GR\\?1RC)?@9'X^G]O3]
MJX?M9+^QM_PS?\$S\4F\$GQ]_:X^//BW_A"%T'[";L%M3/P<_MS[=N`@-JOA
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M.A7%E9ZW\1OA/\1O`>D7>IO-'IUGJGB_P;K'A_3[K4'MX;BX2RM[W489KQH(
M)IQ;)(8899`D;>WC/:_5L1*C_&CA\0Z*VO5]C-P_%$1UE%=W^J_S/SG_`&>_
M^"A/QM_:.^%>B?%CPK\,_P!EKPGHFO76L6MKHGQ%_:MU/PYXKMWT35+G2;J2
M_P!'M?@OK"VD5Q<VDLUD7O"\]FT%UL5)TS^DWP@\1?$3Q1X336?B9X?\`>'M
M:N[MY=+A^&WCO4OB)X9O_#\MO;R:=J<7B+4_!_@J1[JZE-WOMH-*GM8[=+:6
M+4+AIWCA_'7]F/\`8!^._P"S]\']`^%_B7]F']@GXRZOHM]KUY<>/_&6L^('
M\2:NFLZS>:K!#J,M[\#M8FD.F0W::7:M]N=/L=G`%CB8/G]:_@+9?%#2?"4F
MA?$KP!\)OARNAR6>F>$/#?P<\0ZSKGA:U\-VMC!'##Y.K^#?!B:/+:7"RVUO
MI^GV,]F+..!Q)!(7MT^;X>K9K*GA8YLL?]:^JR==5J4_8^V37-S3ITOJT7LH
MVK3YM;)6-:RIJ;5)W7Z=+/7S^??<]SI"0H+,0``22>``.I)I:AG@CN8I()E#
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M3Y>16M*<K2FM/OU6EGUU/J>BBBOKS`\;_:%^*C_`[X'?%OXQ1Z.GB&3X8_#O
MQAXZCT*2];3DU>3PQH5YJT>GO?K;7;6BW4EJL3SI:W#Q([.D,C*%/A?[)G[:
MWP[_`&D/@!X`^,GB#6?`?PWUGQA:ZU)J7@F\\?:)=76@W6C^)=9\/M;S3WK:
M3=-]JCTJ/4X?/TZUD%M?P?NW7;-+ZY^U#\--<^-'[.OQN^$?AJ[T^Q\0?$KX
M6^./`^C7NKO<1Z7;:KXC\/WVE6,U_):075S'9I<W2/<R06T\D4*NZQ.P"GY9
M_8S_`&`OAG\%/V;OAI\,?C)\*/@AX[^)/AFQUQ?%7BF/P+H'B+^U[W5?%FOZ
MY;2#6?$/ARVU>_\`LFEZE8:<9[R&-PUFT,:""*//S->><K.J,<)&E/*Y994=
M2=9U(4'C?K<(0M4ITZK]KR3ERTW%*2B_>5KFJ5-4I2G\?,N3O%):^;YKK[NE
MR_X)_;XTKQ[^WCXJ_8X\.>&M!U?0?#?PMB^("?%+1?&-MJ\-]J!M?#E[/H:Z
M38V,MF@MX?$"123?VT]PDT#;K0(Q*?HG7Y4_#/\`8)U?X6?\%&_&7[5?@^P^
M&OA+X+:]\'D\$:9X*\)V4FB:O:>(GM?"MK>7KZ#IVB6>@0VER^@7-U+=PZBU
MS.\T(EM_,RQ_5:NS(Y9G*EC?[5@HUEF6*5#E?-!X-<GU=TY64IT[<W+*2BWK
MHK"J>S]SV:_Y=0<]]9M.[\KZ:!1117M&84444`>#_M,?&&;]GWX!_%;XTP:`
MGB>7X:^#-8\5QZ!+?G2X]5DTVW61;-]0%K>M:+*YPTPM9BHSMC9L"LC]DSX[
M2_M,?L[?"WXZ3^'(_"4_Q&T"?69?#<.I-K$>E/!JVI:0T":DUG8/=*[:?YZN
MUG`0)/+*Y0DG[7/PFU_X[?LS_&KX.^%;S3;#Q'\1?A_KOA?1;S6I+J'2;?4=
M1MC';R:A-9VM]=0VOF!5DD@L[ET#;EA?:16'^Q/\%?$W[.G[+'P=^"7C&^T?
M4_$_P]\-W&D:S?Z!-=W&CW%U<:YJVJYL)[ZTL+N6*.+4(XB\]E;,SHY$:J5K
MQ%+,/]8%#V<UE7]E2ESM)4_KT,;!K6]^;V;=DU:VMC3E7L.:_O<ZA;KRM+6]
M^_2S_5?5=%%%>V9GX>^&O^"R^CV_QF^*7A'XL_`_6O`WP5^&_P`8]?\`@MJ?
MQWT77+CQ9H_ASQ/8:[K.D^'9O'>BV^A6MYH.E^)HM#OI(M1M[B\2RNH9;40W
MBV]Q-%];?MA?MX:?^S-H_P"SCXA\+>$])^*N@?M`?$W0_`]CK.G>+(K/3;/1
M-:CLYH/$.D:A8Z;K5KK7VBVO$GLD$MK:21HS/>*"-OF7['O[!?B+X1^+/VY_
M^%X1_#OQ]\.OVIOBG/XPT?PQ;+>ZW;R>'+O7?'^ISV'BO3M9T6QM(;LVWBO2
MT2*QGU.-+FREGBNXVCMV;Y'^+O\`P2'^+\/B_P"&_AGX`?&'2A^S#X1^,_AC
MXQV?PE^*E]KU[JOPQU?2[Z1M<T[X;Z[;:7K,]_H.K:?<W+PZ'JLVG"WU%([F
MYN[R[5M2D_.?;<9T<JJ2]C4Q>*Q6+E"DFL/1Q.7QCF4:,)2C[L:^&Q&#CS^U
MYX5*/M&G3DDF^Q/"NI'3EA#XHZM3NMKKX>7?KOTMK_0C1117Z*KV5^QQGY^_
MM!_M]>$OA#\9O!O[,?PZ\!>(/CC^TGX[ACNM(^&WAS5-+\.:7HFG26%]JR:K
MXU\8ZOYMCH%G_8^F:CK#1V]CJM\FEVC74]K`EQ9FYZH^,OV]X[>'4/\`A1'[
M-5P7,;3>'X_C_P"/(M3MHI"`\?\`:\GP2?39[B#K(5@6&0*WE,W&?%?V@_V#
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M-+35?LZ#45TR2[CANY+`78E^R/<1QSM`4\U%DW5KU];%MI-]4G^!S!1113`*
M***`.>\4>%?#WC71-1\->+-%TKQ'X=UBTEL=6T/6["TU72=3LYUVS6M_IU_!
M<V=W!(N`T4\+H<#(K\._VF/^"#/[.'Q/NK_Q'\"_$FO?`7Q%?-+<-H=O`WB[
MX<O=$M(?LV@WUY9ZWH*SRORND>(!I=I&,6VB87R9/WEHKQLUX?RG.J7LLSP=
M'$Q4>6$W!1KPCI=0K*\E>RVL:4ZM2E)2IRY>ZW3[?<?Q3>,_^")/_!0;X2ZJ
M^H_#&'PI\0/LLCRV&L?#;XB1^%]7C`95C=K7Q?)X+N+:[*;7*VVH7ZQ*-J2R
MO&&',Q_L_?\`!:[P\O\`9=I9_MBV\4&%6+2OBGXGN[)%`"J(9].\:W%DZ\$_
MN9"1GYB<K7]O]%?'2\,,IC98/-<\P--?\NJ&-3IZ6V52G*VSVMOK>R.E8VIU
MA3EZP7Z'\/,_[`/_``5V^.'EV7C7PG\:-:L)6'G3?%GXQ6$5C&KD$--I_B?Q
MQ-?-CYLF+3KJ50B[HV5]I^MO@C_P;U_%?5KNTU+]H'XQ^%O!FEEUFNM`^&UI
M>^,/$4Z%ED-L^M:Q::'HFE7&1(3<V]CXFCW,2(Y,B5?ZT**O"^&'#]*HJN-K
M9CFDE\4,;B(NC/\`Q0I4J<[>4:D5O>X?7JJ^!0I]/<5K[;_UU9\5_LO?\$_O
MV8/V1+*,_"3P!;KXJ:W^SZA\1O$\J>(?'VI(Z;)U?7+N%4TJUN>6N-,\.VFC
M:7*Y,CV1E>1V^U***^]P>"PF7T(8;!8>EAJ$/@I48*$(^B6AR2E*<G*3<I/=
MO=A111742%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
+`%%%%`!1110!_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
